Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

Y0000750

Dorzolamide for system suitability

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

Dorzolamide hydrochloride

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C10H16N2O4S3 · HCl
Número de CAS:
130693-82-2
Peso molecular:
360.90
Beilstein:
5896026
Número MDL:
MFCD00884659
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329831128
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

dorzolamide

fabricante / nombre comercial

EDQM

aplicaciones

pharmaceutical (small molecule)

Formato

neat

cadena SMILES

Cl.CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O

InChI

1S/C10H16N2O4S3.ClH/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16;/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16);1H/t6-,8-;/m0./s1

Clave InChI

OSRUSFPMRGDLAG-QMGYSKNISA-N

Información sobre el gen

human ... CA2(760)

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Dorzolamide for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

Y0000726

Dorzolamide hydrochloride, European Pharmacopoeia (EP) Reference Standard

1225281

Dorzolamide hydrochloride, United States Pharmacopeia (USP) Reference Standard

Y0000727

Dorzolamide Impurity A, European Pharmacopoeia (EP) Reference Standard

1225292

Dorzolamide hydrochloride Related Compound A, United States Pharmacopeia (USP) Reference Standard

1225306

Dorzolamide Related Compound D, United States Pharmacopeia (USP) Reference Standard

BP1069

Dorzolamide hydrochloride, British Pharmacopoeia (BP) Reference Standard

PHR1925

Dorzolamide hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

BP1071

Dorzolamide impurity D, British Pharmacopoeia (BP) Reference Standard

BP1070

Dorzolamide impurity B, British Pharmacopoeia (BP) Reference Standard

Pictogramas

Health hazardExclamation mark
GHS08,GHS07

Palabra de señalización

Warning

Frases de peligro

H302,H373

Clasificaciones de peligro

Acute Tox. 4 Oral - STOT RE 2

Órganos de actuación

Central nervous system,Gastrointestinal tract,Bone,Blood,Bladder

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Ikuyo Ohguro et al.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 28(4), 392-396 (2012-04-07)
The purpose of the present study is to evaluate the effects of a fixed combination of 0.5% timolol maleate (TM) and 1% dorzolamide hydrochloride (DZ) (FCTD(1%)) on optic nerve head (ONH) blood circulation. A drop of 0.5% TM, 1% DZ
Vikas Gulati et al.
Archives of ophthalmology (Chicago, Ill. : 1960), 130(6), 677-684 (2012-02-15)
To evaluate the interaction of intraocular pressure(IOP)–lowering medications with physiologic day and night changes in aqueous humor dynamics in participants with ocular hypertension. Thirty participants were enrolled in thisdouble-masked, randomized, crossover study. Each participant underwent aqueous humor dynamics measurements at
Yasuhiro Ikeda et al.
The British journal of ophthalmology, 97(9), 1187-1191 (2013-06-21)
To evaluate the therapeutic effect of continuous treatment with topical dorzolamide (a carbonic anhydrase inhibitor) for cystoid macular oedema (CME) associated with retinitis pigmentosa (RP). 18 eyes in 10 patients with CME secondary to RP were included. Baseline visual acuity
Mohamed A Genead et al.
Retina (Philadelphia, Pa.), 32(4), 826-833 (2011-09-03)
: To determine the value of a topical carbonic anhydrase inhibitor on the macular thickness and function in choroideremia patients with cystoid macular edema. : Two choroideremia patients with cystoid macular edema, observed by spectral-domain optical coherence tomography, were treated
Kelly J Sigle et al.
Veterinary ophthalmology, 14 Suppl 1, 48-53 (2011-09-23)
To determine the extent of fluctuation in circadian intraocular pressure (IOP) and the efficacy of topical dorzolamide 2% q 8 h in lowering IOP and blunting circadian fluctuation in IOP in glaucomatous cats. Seven adult cats with primary congenital glaucoma
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico